Selah Therapeutics' is joint venture Juvenescence & the Buck Institute for heart disease. It will focus on developing novel ketone-based therapies for the treatment of heart diseases, in particular heart failure. Selah combines the deep proprietary expertise in the science of ketones along with an extensive library of novel compounds from The Buck Institute of Aging with the strong science and extensive drug discovery and development experience from Juvenescence. By focusing on ketones, Selah will develop first-in-class therapies with a novel mechanism that improves the well-being of the patient with heart disease.